65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00325078 (ClinicalTrials.gov) | May 2006 | 11/5/2006 | Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease | Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences | Chronic Granulomatous Disease;Crohn'S-like IBD;Inflammatory Bowel Disease (IBD) | Drug: Infliximab | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Terminated | 10 Years | N/A | All | 40 | Phase 1/Phase 2 | United States |